zopapogene imadenovec
AXP000159.1 · Cancer vaccine
- Platform
- gorilla adenovirus (AdenoVerse, non-replicating)
- Originator
- Precigen
- Sponsor
- Precigen
Names
| Name | Type | Source |
|---|---|---|
| zopapogene imadenovec | preferred name, INN | curator, ncit |
| Papzimeos | brand | fda |
| zopapogene imadenovec-drba | USAN | fda |
| PRGN-2012 | code | ncit |
| Gorilla-derived Adenovirus-expressing HPV-6/11 Vaccine PRGN-2012 ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- gorilla adenovirus
- Replication
- non replicating
- Modifications
- non-replicating gorilla adenovirus vector (AdenoVerse platform)
- Transgenes
- HPV-6 and HPV-11 antigens
- Route
- subcutaneous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C207022
- FDA UNII
- C525BYS7TP
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2025-08-14 | approved | Papzimeos | Treatment of adults with recurrent respiratory papillomatosis | source |
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07901738 | Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children | Not yet recruiting | Phase 3 | 2026-12-31 | 2029-01 | 15 | Juvenile-onset Recurrent Respiratory Papillomatosis; Papillomavirus Infections; Recurrent Respiratory Papillomatosis (RRP) |
| NCT07756840 | Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) | Not yet recruiting | Phase 2 | 2026-11-18 | 2029-07-01 | 50 | Human Papillomavirus (HPV); Laryngeal Diseases; Papillomavirus Infection; Respiratory Recurrent Papillomatosis (RRP); Respiratory Tract Neoplasm; Tracheal Diseases |
| NCT06538480 | Zopa Retreatment and Vector Shedding in Adults With RRP | Recruiting | Phase 4 | 2024-07-11 | 2027-12-02 | 30 | Papillomaviridae; Papillomavirus Infection; Recurrent Respiratory Papillomatosis |
| NCT04724980 | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | Active not recruiting | Phase 1/2 | 2021-03-16 | 2024-06-05 | 38 | Papillomaviridae; Papillomavirus Infections; Recurrent Respiratory Papillomatosis |
Recent changes
| Seen | Trial | Change | Detail | Title |
|---|---|---|---|---|
| 2026-11-12 | NCT07901738 | new trial | Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children |
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39855244 | PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. | The Lancet. Respiratory medicine | 2025 | name in title: PRGN-2012 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41205140 | Zopapogene Imadenovec: First Approval. | Molecular diagnosis & therapy | 2026 | name in title: zopapogene imadenovec |
| PMID 41720607 | Therapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years. | Journal for immunotherapy of cancer | 2026 | name in abstract: zopapogene imadenovec |
| PMID 42103572 | The Efficacy and Safety of Systemic Treatment for Managing Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-analysis. | Journal of voice : official journal of the Voice Foundation | 2026 | name in abstract: zopapogene imadenovec-drba |
| PMID 42248643 | Non-replicating adenoviral vectors for cancer gene therapy. | Advances in cancer research | 2026 | name in abstract: Papzimeos |
| PMID 42438380 | Zopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis. | The Annals of pharmacotherapy | 2026 | name in title: zopapogene imadenovec-drba |
| PMID 40307073 | Disease Control and Voice Outcomes Following Treatment With PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis. | Journal of voice : official journal of the Voice Foundation | 2025 | name in title: PRGN-2012 |
| PMID 41020881 | Emerging Therapeutic Strategies for HPV-Related Cancers: From Gene Editing to Precision Oncology. | Current issues in molecular biology | 2025 | name in abstract: PRGN-2012 |
| PMID 41377441 | From surgery to immunotherapy: Papzimeos as the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP). | Annals of medicine and surgery (2012) | 2025 | name in title: Papzimeos |
| PMID 37878675 | The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis. | Science translational medicine | 2023 | name in abstract: PRGN-2012 |
| PMID 34145272 | Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. | NPJ vaccines | 2021 | name in abstract: PRGN-2012 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| U01CA298630 | Cell-Cell Signaling Driving HPV-Induced Respiratory Disease and Vaccine Response | CINCINNATI CHILDRENS HOSP MED CTR | WELLS, SUSANNE I | 2025–2026 | name in abstract: PRGN-2012 |
| ZIABC010598 | Human Immune Responses to Tumor Antigens for Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2012–2025 | name in abstract: PRGN-2012 |
| ZIABC010666 | Cancer Immunotherapy | DIVISION OF BASIC SCIENCES - NCI | GULLEY, JAMES L. | 2009–2025 | name in abstract: PRGN-2012 |
| ZIDDC000075 | NIDCD Core for Clinical Research and Care | NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS | LEVY, JOSHUA | 2021–2025 | name in abstract: PRGN-2012 |
| ZIABC010425 | Strategies for Cancer Immunotherapy Clinical Trials | DIVISION OF BASIC SCIENCES - NCI | SCHLOM, JEFFREY | 2009–2023 | name in abstract: PRGN-2012 |
Notes
PRGN-2012: non-replicating gorilla adenovirus expressing HPV 6 and HPV 11 antigens, given as four subcutaneous injections over 12 weeks. FDA approved 14 August 2025 as Papzimeos (STN 125832, proper name zopapogene imadenovec-drba) for recurrent respiratory papillomatosis in adults: the first approved therapy for that disease, and a full rather than accelerated approval. A therapeutic vaccine against an HPV-driven benign neoplasm; recorded here as a cancer vaccine. The exact gorilla adenovirus serotype of the AdenoVerse vector is not stated in the sources used.
How to cite
zopapogene imadenovec (AXP000159.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000159.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.